论文部分内容阅读
目的观察阿托伐他汀联合非诺贝特降血脂的有效性及安全性。方法将混合性高胆固醇血症患者随机分为单用阿托伐他汀组(单用组)80例,阿托伐他汀联合非诺贝特组(联合治疗组)82例,分析其疗效与不良反应。结果两组治疗8周后的血清TC、TG、LDL水平与治疗前相比,差异有统计学意义,联合治疗组HDL水平升高;联合治疗组较单用组比较差异有统计学意义(P﹤0.05)。治疗后12月,两组TC、TG、LDL、Lp(a)水平继续降低,HDL水平继续升高,与治疗8周比较差异有统计学意义(P﹤0.05);联合组较单用组比较差异有统计学意义(P﹤0.05)。两组不良反应差异无统计学意义(P﹥0.05)。结论与单用阿托伐他汀相比,阿托伐他汀联合非诺贝特具有更好的调节血脂的作用。
Objective To observe the efficacy and safety of atorvastatin combined with fenofibrate in lowering blood lipid levels. Methods A total of 80 patients with mixed hypercholesterolemia were randomized into atorvastatin alone group (single use group) and 82 patients with atorvastatin combined with fenofibrate group (combined treatment group) reaction. Results The serum levels of TC, TG and LDL in the two groups after 8 weeks of treatment were significantly different from those before treatment, and the levels of HDL in the combined treatment group were increased. The difference between the two groups was statistically significant (P <0.05). The levels of TC, TG, LDL and Lp (a) in the two groups continued to decrease and the level of HDL continued to increase in 12 months after treatment. There was a significant difference between the two groups (P <0.05) The difference was statistically significant (P <0.05). There was no significant difference in adverse reactions between the two groups (P> 0.05). Conclusion Compared with atorvastatin alone, atorvastatin combined with fenofibrate had better lipid-lowering effect.